Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more
Head-to-head evidence comparison — which supplement is right for you?
Berberine wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Likely helps
12 of 16 studies with measurable effects showed benefit.
Top outcomes
Verdict
Likely helps
6 of 6 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both Berberine and PEA have evidence — compare verdict strength side-by-side.
500mg 2-3x daily (1000-1500mg total)
With meals, Split into 2-3 doses
Berberine HCl capsules
600-1200mg
With meals, Split into 2-3 doses
Micronized or ultra-micronized PEA
4-12 weeks
8-12 weeks
First 2 weeks
If on diabetes medications
2-8 weeks
4-8 weeks
Ongoing
Clinical Efficacy of Curcumin, Resveratrol, Silymarin, and Berberine on Cardio-Metabolic Risk Factors Among Patients With Type 2 Diabetes Mellitus: A Systemic Review and Bayesian Network Meta-Analysis
Phytotherapy research : PTR (2025) · Meta analysis · n=1337
For HbA1c, silymarin was more effective than resveratrol (MD -2.08, 95%Cl -3.50 to -0.72) (P < 0.05).
Effects of berberine and barberry on selected inflammatory biomarkers in adults: A systematic review and dose-response meta-analysis of randomized clinical trials
Phytotherapy research : PTR (2023) · Meta analysis · n=1600
In addition, the non-linear analysis showed a significant lowering effect of berberine/barberry on IL-6 and TNF-α levels in doses <1000 mg/day and less than 5 weeks of intervention.
Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical Trial
JAMA network open (2025) · Rct · n=113
The study included 113 patients with T2D (mean [SD] age, 54.3 [10.6] years; 72 male [63.7%]) who were randomized.
Extended Treatment with Micron-Size Oral Palmitoylethanolamide (PEA) in Chronic Pain: A Systematic Review and Meta-Analysis
Nutrients (2024) · Meta analysis · n=742
These two obtained scores corresponded to a 35.1% pain intensity reduction within the first month, followed by a further 35.4% during the second month.
Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials
Nutrients (2023) · Meta analysis · n=774
PEA was found to reduce pain scores relative to comparators in a pooled estimate, with a standard mean difference of 1.68 (95% CI 1.05 to 2.31, p = 0.00001).
Navigating agitation in neurodevelopmental disorders: A comparative study of pharmacotherapies via network meta-analysis in children and adults with autism spectrum disorder or intellectual disabilities
Journal of psychopharmacology (Oxford, England) (2025) · Meta analysis · n=2503
Importantly, these treatments were generally well-tolerated, with no significant increase in all-cause dropouts compared to placebo, highlighting their suitability for clinical use in managing agitation in individuals with ASD or ID.
Based on meta-analyses showing FPG reduction of 0.59-0.82 mmol/L and HbA1c reduction of 0.63%. Studies primarily used berberine HCl with low bioavailability. Effects require divided doses and may take 8-12 weeks.
Based on multiple meta-analyses showing ~35% pain reduction. Studies primarily used micronized formulations which may have better bioavailability than standard forms. Most benefits observed within 4-6 weeks of treatment.
AI-estimated from published studies. Interpret as directional guidance.
Berberine has a higher evidence score (9/10 vs 8.5/10) and wins in 2 of 3 categories.
For reduce inflammation, Berberine has a higher relevance score (95 vs 85).
No known interactions between Berberine and PEA have been documented in our database. However, always consult a healthcare provider before combining supplements.